Introduction to Growth Hormone Secretagogues
Understand how GH secretagogues like CJC-1295 and Ipamorelin work, how they differ from exogenous GH, and why they're popular in research.
What Are Growth Hormone Secretagogues?
Growth hormone secretagogues (GHS) are a class of compounds that stimulate the body's own production and release of growth hormone (GH) from the pituitary gland. Unlike exogenous growth hormone — which introduces synthetic GH directly — secretagogues work with the body's natural feedback systems to elevate GH in a pulsatile, physiological pattern.
This distinction matters. The body releases GH in pulses, not as a steady stream, and secretagogues preserve that natural rhythm.
Two Key Pathways
The pituitary gland responds to two main signals for GH release:
GHRH Pathway (Growth Hormone-Releasing Hormone)
GHRH is produced by the hypothalamus and tells the pituitary to synthesize and release GH. CJC-1295 is a synthetic GHRH analog — it mimics this "go" signal.
Ghrelin/GHS-R Pathway
Ghrelin receptors on the pituitary respond to a separate signal that amplifies GH release. Ipamorelin binds this receptor, acting as a GH secretagogue through the ghrelin pathway.
When both pathways are activated simultaneously, the GH response is synergistic — significantly greater than either signal alone. This is why CJC-1295 and Ipamorelin are frequently studied together.
CJC-1295: The GHRH Analog
CJC-1295 comes in two forms in the research literature:
CJC-1295 with DAC
The Drug Affinity Complex (DAC) modification allows CJC-1295 to bind to serum albumin, extending its half-life from minutes to 6–8 days. This creates a sustained elevation of baseline GH levels.
- Dosing: Typically 1–2mg, 1–2x per week
- Profile: Sustained GH elevation, gradual onset
- Best for: Researchers studying long-term GH effects
CJC-1295 without DAC (Modified GRF 1-29)
Without the DAC modification, this peptide has a shorter half-life (~30 minutes) and produces acute GH pulses rather than sustained elevation.
- Dosing: Typically 100mcg, 1–3x daily
- Profile: Sharp GH pulses, short duration
- Best for: Researchers studying pulsatile GH dynamics
Ipamorelin: The Clean GHS
Ipamorelin stands out among ghrelin-receptor agonists for its selectivity. Compared to earlier GHS peptides like GHRP-6 and GHRP-2:
| Property | GHRP-6 | GHRP-2 | Ipamorelin | |----------|--------|--------|------------| | GH Release | Strong | Strong | Strong | | Cortisol Increase | Significant | Moderate | Minimal | | Prolactin Increase | Moderate | Moderate | Minimal | | Appetite Stimulation | Strong | Mild | None |
This selectivity makes Ipamorelin valuable for research where confounding hormonal changes would complicate data interpretation.
The CJC-1295 + Ipamorelin Stack
The combination of CJC-1295 (GHRH pathway) and Ipamorelin (ghrelin pathway) is one of the most studied peptide stacks in GH research. The rationale is straightforward:
- CJC-1295 primes the pituitary to produce GH
- Ipamorelin amplifies the release signal
- The combined effect exceeds the sum of either peptide alone
Typical research protocols administer both peptides simultaneously, often before sleep to coincide with the body's natural nocturnal GH surge.
How GHS Peptides Differ from Exogenous GH
| Factor | Exogenous GH | GH Secretagogues | |--------|-------------|------------------| | Source | Synthetic GH injected directly | Body's own GH, stimulated to release | | Release pattern | Steady, non-physiological | Pulsatile, physiological | | Feedback loop | Suppresses natural production | Works within natural feedback | | IGF-1 spike | Can cause supraphysiological levels | Elevation within physiological range | | Cost | Very high | Moderate |
The key advantage of secretagogues is that the body's negative feedback systems remain intact. When GH levels rise too high, somatostatin naturally suppresses further release — a safety mechanism that exogenous GH bypasses entirely.
AOD-9604: A Related Fragment
While not a secretagogue, AOD-9604 deserves mention here. It's a modified fragment of human growth hormone (amino acids 176–191) that retains GH's fat-metabolizing properties without affecting blood sugar or IGF-1 levels.
AOD-9604 works downstream of where secretagogues act — it mimics one specific effect of GH rather than stimulating GH release. It's sometimes included in metabolic research protocols alongside GHS peptides.
Research Considerations
When designing research protocols involving GH secretagogues:
- Timing matters: GH release follows circadian patterns. Pre-sleep administration aligns with natural GH surges.
- Fasted state preferred: Food intake (especially fats and carbohydrates) can blunt the GH response to secretagogues.
- Cycle length: Most protocols run 8–12 weeks, followed by a washout period.
- Measurement: Serum IGF-1 is a common proxy for sustained GH activity, as GH itself has a very short half-life and is released in pulses.
Key Takeaway
GH secretagogues offer a way to study elevated growth hormone within physiological parameters. CJC-1295 and Ipamorelin represent the two major pathways for GH stimulation, and their combination produces a synergistic response that has made them among the most popular research peptides in the field.